Evercore ISI analyst Daniel Markowitz CFA has reiterated their bullish stance on WST stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Markowitz CFA has given his Buy rating due to a combination of factors influencing West Pharmaceutical Services. One of the primary reasons is the strong performance of their High-Value Products (HVP) components, which have shown significant margin recovery and an upward revision in their full-year guidance. This indicates a promising growth trajectory, supported by the increasing number of projects that are expected to contribute positively in the coming years, particularly in 2026 and 2027.
Additionally, the company is poised to deliver strong results in the second half of the year, with improved visibility as destocking winds down and custom ordering patterns stabilize. The guidance for the second half remains conservative, despite the positive outcomes from the second quarter and a favorable foreign exchange and tariff outlook. These factors, combined with a unique customer situation and a robust pipeline of projects, set the stage for continued momentum into 2026, justifying the Buy rating.
Markowitz CFA covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Repligen, and Guardant Health. According to TipRanks, Markowitz CFA has an average return of -10.0% and a 0.00% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also upgraded the stock to a Buy with a $252.00 price target.